“You can be 2 to 3 mm from another organ and still safely treat the tissue that you want to,” says Jennifer Linehan, MD.
In this video, Jennifer Linehan, MD, discusses the what makes high-intensity focused ultrasound (HIFU) unique compared to other treatment options for prostate cancer and how minimally invasive and robotic therapies like HIFU have changed the space. Linehan is an associate professor of urology and urologic oncology at the John Wayne Cancer Institute in Santa Monica, California.
Targeted radiation plus systemic therapy combo shows promise in mHSPC
March 18th 2024"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.
Relugolix plus radiotherapy shows safety, efficacy in prostate cancer
March 14th 2024“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.